Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Nefopam hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Nefopam hydrochloride tablet belongs to a group of medicines called analgesics, commonly known as pain killers or pain relievers. The active substance, nefopam hydrochloride, interrupts the pain messages being sent to your brain, and it also acts in your brain to stop pain messages being felt. This means that nefopam hydrochloride does not stop the pain from happening, but you will not be able to feel the pain as much. Nefopam hydrochloride is used to relieve of acute and chronic pain (for example pain after an operation, dental pain, joint or muscle pain, after an injury, or pain caused by cancer). Nefopam hydrochloride should not be used to treat the pain from a heart attack
e Nefopam hydrochloride tablet Do not take nefopam hydrochloride if: –
you are a child under 12 years old
–
you have ever had an allergic reaction to nefopam hydrochloride or any of the ingredients resulting in a skin rash, swelling of the face or difficulty in breathing (see section 6. Contents of the pack and other information)
–
you are taking monoamine oxidase inhibitors (MAOIs) to treat your depression
–
you have, or have ever had, epilepsy (fits).
Warnings and precautions Talk to your doctor or pharmacist before taking nefopam hydrochloride
If the answer to any of the following is 'yes', you must tell your doctor – your doctor may decide to alter your treatment.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines:
Nefopam hydrochloride tablet Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Dosage for adults: The usual initial dose is two tablets taken three times a day. Your doctor may increase this dose up to a maximum of three tablets taken three times a day according to your needs. Ask your doctor or pharmacist if:
Dosage for children: Over 12 years – as per adults (see above). Under 12 years – Nefopam hydrochloride should not be taken by children under 12. Dosage for older patients: In older patients the doctor may reduce the number of tablets that are taken. Dosage for patients with kidney and/or liver problems: Your doctor may adjust the dose of nefopam hydrochloride depending upon your condition. If you take more Nefopam hydrochloride tablets than you should If you accidentally take more tablets than your prescribed dose, tell your doctor or pharmacist immediately and if necessary contact your nearest hospital casualty department. Remember to take the pack and any remaining medicines with you. If you forget to take Nefopam hydrochloride tablets If you forget to take nefopam hydrochloride, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose. If you stop taking Nefopam hydrochloride tablets Do not stop taking nefopam hydrochloride without first checking with your doctor. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Please stop taking this medicine and contact your doctor as soon as possible if you experience the following rare reactions:
which may occur most frequently include:
5.
Nefopam hydrochloride tablets
Keep this medicine out of the sight and reach of children. This medicinal product does not require any special storage conditions. Do not use this medicine after the expiry date which is stated on the blister label and the carton after EXP. The expiry date refers to the last day of that month. Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicine you no longer use. These measures will help protect the environment.
6.
What Nefopam hydrochloride tablet contains • •
The active substance is nefopam hydrochloride The other ingredients are: Tablet Core: Microcrystalline cellulose, Pregelatinized starch, Dicalcium phosphate dihydrate, Silica colloidal anhydrous, Magnesium stearate, Tablet Film-coating: Hypromellose (6cP), Titanium dioxide (E171), Macrogol.
What Nefopam hydrochloride tablet looks like and contents of the pack Nefopam hydrochloride tablets are white to off white, round shape, film coated tablets debossed with "EM" on one side and "62" on the other side The tablets are available in aluminium-PVC/PVDC blister or aluminium-PVC blister with 30's and 90's tablets Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer Tillomed Laboratories Limited 220 Butterfield Great Marlings Luton LU2 8DL United Kingdom This leaflet was last revised in February 2026
Nefopam hydrochloride 30 mg film-coated tablets comes as tablet containing 30mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Nefopam hydrochloride 30 mg film-coated tablets is nefopam hydrochloride.
Medicines with the same active substance, strength and form include: Nefopam Hydrochloride 30 mg Film-coated Tablets, Nefopam hydrochloride 30 mg Film-coated Tablets. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Nefopam hydrochloride 30 mg film-coated tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Nefopam hydrochlorideis indicated for the relief of acute and chronic pain including post-operative pain, dental pain, musculo-skeletal pain, acute traumatic pain and cancer pain.
Posology
Adults
Dosage may range from 1 to 3 tablets three times daily depending on response. The recommended starting dosage is 2 tablets three times daily.
Special population
Elderly
Older patients may require reduced dosage due to slower metabolism. It is strongly recommended that the starting dose does not exceed one tablet three times daily as older people appear more susceptible to, in particular, the CNS side effects of nefopam hydrochloride and some cases of hallucinations and confusion have been reported in this age group.
Paediatric population
The safety and efficacy of nefopam hydrochloride in children under 12 years has not yet been established. No dosage recommendation can be given for patients under 12 years.
Patients with end-stage renal disease might experience increased serum peak concentrations during treatment with nefopam. In order to avoid that, it is recommended the daily dose should be reduced not only for the elderly, but also for patients with terminal renal insufficiency.
Method of Administration
Oral.
Nefopam hydrochloride is contraindicated in patients with a history of convulsive disorders and shouuld not be given to patients taking mono-amine oxidase (MAO) inhibitors. Nefopam hydrochloride is contraindicated in patients with known hypersensitivity to any of the ingredients.
The side effects of nefopam hydrochloride may be additive to those of other agents with anticholinergic or sympathomimetic activity. It should not be used in the treatment of myocardial infarction since there is no clinical experience in this indication. Hepatic and renal insufficiency may interfere with the metabolism and excretion of nefopam.
Nefopam should be used with caution in patients with angle closure glaucoma.
Drug dependence
Use of nefopam may lead to drug dependence, which may result in drug abuse, particularly in patients with a history of substance use and/or mental health disorders. In such patients, nefopam should be prescribed with caution, and signs of dependence should be monitored.
Nefopam hydrochloride should be used with caution in patients with, or at risk of, urinary retention.
Rarely a temporary, harmless pink discolouration of the urine has occurred.
Caution should be exercised when nefopam is administered concurrently with tricyclic antidepressants.
It should be noted that nefopam may interfere with some screening tests for benzodiazepines and opioids. These tests for benzodiazepines and opioids may give false positive results for patients taking nefopam hydrochloride.
There is no evidence as to the drug safety in human pregnancy, nor is there evidence from animal work that it is free from hazard. Avoid in pregnancy unless there is no safer treatment
Not applicable
Nausea, nervousness, dry mouth and light-headedness, urinary retention, hypotension, syncope, palpitations, gastrointestinal disturbances (including abdominal pain and diarrhoea), dizziness, paraesthesia, convulsions, tremor, confusion, hallucination, angioedema, and allergic reactions may occur.
Less frequently, anaphylactic reactions, coma, vomiting, blurred vision, drowsiness, sweating, insomnia, headache and tachycardia have been reported.
System Organ Class
Frequency
Adverse Reaction
Psychiatric disorders
Rare
Drug dependence
Drug dependence
Use of nefopam can lead to drug dependence. The risk of drug dependence may vary depending on a patient's individual risk factors (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The clinical pattern of nefopam toxicity in overdose is on the neurological (coma, convulsions, hallucinations and agitation) and cardiovascular systems (tachycardia with a hyperdynamic circulation). Routine supportive measures should be taken and prompt removal of ingested drug by gastric Lavage or induced vomiting with Syrup of Ipecacuanha should be carried out. Oral administration of activated charcoal may help prevent absorption.
Convulsions and hallucinations should be controlled (eg with intravenously or rectally administered diazepam). Beta-adrenergic blockers may help control the cardiovascular complications.
Ask anything about Nefopam hydrochloride 30 mg film-coated tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.